Cutting back the thickets of Biosimilars
Biosimilars in Italy: a new regime
roschetzky / iStockphoto
Introducing more biosimilars could cut healthcare spending by $54 billion over the next ten years, a figure far higher than initially thought, a think tank and research organisation has claimed.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at firstname.lastname@example.org
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Rand Corporation, biosimilars, biologics, "Biosimilar Cost Savings in the US”; Zarxio, Amgen, Sandoz